Updates are available Correction dated 2024-04-29
Click to view Correction: https://doi.org/10.1186/s13024-024-00729-5
-
Authors
Acquarone, Erica
Argyrousi, Elentina K.
van den Berg, Manon
Gulisano, Walter
Fà, Mauro
Staniszewski, Agnieszka
Calcagno, Elisa
Zuccarello, Elisa
D’Adamio, Luciano
Deng, Shi-Xian
Puzzo, Daniela
Arancio, Ottavio https://orcid.org/0000-0001-6335-164X
Fiorito, Jole
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01AG049402)
Alzheimer's Association (AARF-17-504483)
- License Information
-
More Information
Article History
Received: 8 March 2019
Accepted: 5 June 2019
First Online: 27 June 2019
Change Date: 29 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13024-024-00729-5
Ethics approval
: All animal experiments were approved by the ethical committee of Columbia University (IACUC #: AC-AAAO5301 and AC-AAAQ5429).
: Not applicable.
: OA is a founder of Neurokine Therapeutics. OA has received research funding from Appia Pharmaceuticals LLC. EA, EKA, MVdB, WG, MF, AS, EC, EZ, LD, SXD, PD, and JF declare that they have no competing interests.
